Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2014

Open Access 01-08-2014

Adipose Tissue Immune Response: Novel Triggers and Consequences for Chronic Inflammatory Conditions

Authors: Giorgio Ghigliotti, Chiara Barisione, Silvano Garibaldi, Patrizia Fabbi, Claudio Brunelli, Paolo Spallarossa, Paola Altieri, Gianmarco Rosa, Giovanni Spinella, Domenico Palombo, Razvan Arsenescu, Violeta Arsenescu

Published in: Inflammation | Issue 4/2014

Login to get access

Abstract

Adipose tissue inflammation mediates the association between excessive body fat accumulation and several chronic inflammatory diseases. A high prevalence of obesity-associated adipose tissue inflammation was observed not only in patients with cardiovascular conditions but also in patients with inflammatory bowel diseases, abdominal aortic aneurysm, or cardiorenal syndrome. In addition to excessive caloric intake, other triggers promote visceral adipose tissue inflammation followed by chronic, low-grade systemic inflammation. The infiltration and accumulation of immune cells in the inflamed and hypertrophied adipose tissue promote the production of inflammatory cytokines, contributing to target organ damages. This comorbidity seems to delimit subgroups of individuals with systemic adipose tissue inflammation and more severe chronic inflammatory diseases that are refractory to conventional treatment. This review highlights the association between adipose tissue immune response and the pathophysiology of visceral adiposity-related chronic inflammatory diseases, while suggesting several new therapeutic strategies.
Literature
1.
Dwyer-Lindgren, L., et al. 2013. Prevalence of physical activity and obesity in US counties, 2001–2011: a road map for action. Population Health Metrics 11(1): 7.PubMedCentralPubMedCrossRef
2.
McGorrian, C., et al. 2011. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal 32: 581–589.PubMedCrossRef
3.
Rogge, B.P., et al. 2013. Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis (a SEAS substudy). Journal of the American College of Cardiology.
4.
Bocca, G., et al. 2013. Insulin resistance and cardiovascular risk factors in 3- to 5-year-old overweight or obese children. Hormone Research in Paediatrics 201–206.
5.
Aknc, A., et al. 2013. Association of cardiac changes with serum adiponectin and resistin levels in obese and overweight children. Journal of Cardiovascular Medicine (Hagerstown, Md.) 14(3): 228–234.CrossRef
6.
Smith, S.M., B. Sumar, and K.A. Dixon. 2013. Musculo-skeletal pain in overweight and obese children. International Journal of Obesity (London).
7.
Pinhas-Hamiel, O., et al. 2013. Advanced bone age and hyperinsulinemia in overweight and obese children. Endocrine Practice 1–20.
8.
Salvatore, D., et al. 2013. The prevalence of abnormal metabolic parameters in obese and overweight children. JPEN Journal of Parenteral and Enteral Nutrition.
9.
Yun, C.-H., et al. 2012. Pericardial and thoracic peri-aortic adipose tissues contribute to systemic inflammation and calcified coronary atherosclerosis independent of body fat composition, anthropometric measures and traditional cardiovascular risks. European Journal of Radiology 81: 749–756.PubMedCrossRef
10.
Rosito, G.A., et al. 2008. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117(5): 605–613.PubMedCrossRef
11.
Sogabe, M., et al. 2013. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. Hepatology Research.
12.
Cordeiro, A.C., et al. 2013. Visceral fat and coronary artery calcification in patients with chronic kidney disease. Nephrology, Dialysis, Transplantation.
13.
Ejerblad, E., et al. 2006. Obesity and risk for chronic renal failure. Journal of the American Society of Nephrology 17(6): 1695–1702.PubMedCrossRef
14.
Sturm, W., et al. 2009. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) 17(9): 1783–1788.CrossRef
15.
Galassetti, P. 2012. Inflammation and oxidative stress in obesity, metabolic syndrome, and diabetes. Experimental Diabetes Research 2012: 943706–943706.PubMedCentralPubMedCrossRef
16.
Permana, P.A., C. Menge, and P.D. Reaven. 2006. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochemical and Biophysical Research Communications 341(2): 507–514.PubMedCrossRef
17.
Pietilainen, K.H., et al. 2011. Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biology 9(21666801).
18.
Briand, N., et al. 2011. Distinct roles of endothelial and adipocyte caveolin-1 in macrophage infiltration and adipose tissue metabolic activity. Diabetes 60(2): 448–453.PubMedCentralPubMedCrossRef
19.
Isakson, P., et al. 2009. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 58(7): 1550–1557.PubMedCentralPubMedCrossRef
20.
Kanda, H., et al. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 116: 1494–1505.PubMedCentralPubMedCrossRef
21.
Berg, A.H., and P.E. Scherer. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96(9): 939–949.PubMedCrossRef
22.
Ouchi, N., et al. 2003. Obesity, adiponectin and vascular inflammatory disease. Current Opinion in Lipidology 14: 561–566.PubMedCrossRef
23.
Chinetti-Gbaguidi, G., and B. Staels. 2011. Macrophage polarization in metabolic disorders: functions and regulation. Current Opinion in Lipidology 22: 365–372.PubMedCentralPubMedCrossRef
24.
Lafontan, M. 2013. Adipose tissue and adipocyte dysregulation. Diabetes & Metabolism.
25.
Weiss, T.W., et al. 2011. Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease. International Journal of Clinical Practice 65: 939–944.PubMedCrossRef
26.
Kadowaki, T., et al. 2011. Adiponectin, adiponectin receptors, and epigenetic regulation of adipogenesis. Cold Spring Harbor Symposia on Quantitative Biology 76: 257–265.PubMedCrossRef
27.
Hattori, Y., et al. 2008. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Letters 582: 1719–1724.PubMedCrossRef
28.
Haugen, F., and C.A. Drevon. 2007. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148(11): 5478–5486.PubMedCrossRef
29.
Liu, M., and F. Liu. 2010. Transcriptional and post-translational regulation of adiponectin. Biochemical Journal 425: 41–52.CrossRef
30.
Ryo, M., et al. 2004. Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal 68(11): 975–981.PubMedCrossRef
31.
Coughlin, C.C., et al. 2007. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring) 15(3): 640–645.CrossRef
32.
Swarbrick, M.M., et al. 2006. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 49(11): 2552–2558.PubMedCrossRef
33.
Mao, X., et al. 2006. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nature Cell Biology 8: 516–523.PubMedCrossRef
34.
Sag, D., et al. 2008. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. Journal of Immunology 181: 8633–8641.CrossRef
35.
Sasaki, A.T., and R.A. Firtel. 2006. Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. European Journal of Cell Biology 85: 873–895.PubMedCrossRef
36.
Marchesi, C., P. Paradis, and E.L. Schiffrin. 2008. Role of the renin-angiotensin system in vascular inflammation. Trends in Pharmacological Sciences 29: 367–374.PubMedCrossRef
37.
Ishibashi, M., et al. 2004. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circulation Research 94: 1203–1210.PubMedCrossRef
38.
39.
Yvan-Charvet, L., and A. Quignard-Boulange. 2011. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney International 79(2): 162–168.PubMedCrossRef
40.
Makita, S., et al. 2008. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 57: 1473–1478.PubMedCrossRef
41.
Trellakis, S., et al. 2012. Low adiponectin, high levels of apoptosis and increased peripheral blood neutrophil activity in healthy obese subjects. Obesity Facts 5: 305–318.PubMedCrossRef
42.
Elgazar-Carmon, V., et al. 2008. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. Journal of Lipid Research 49: 1894–1903.PubMedCrossRef
43.
Talukdar, S., et al. 2012. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nature Medicine 18: 1407–1412.PubMedCentralPubMedCrossRef
44.
Kurashima, Y., and H. Kiyono. 2014. New era for mucosal mast cells: their roles in inflammation, allergic immune responses and adjuvant development. Experimental and Molecular Medicine 46: e83.PubMedCentralPubMedCrossRef
45.
Hirai, S., et al. 2014. Involvement of mast cells in adipose tissue fibrosis. American Journal of Physiology, Endocrinology and Metabolism 306(3): E247–E255.CrossRef
46.
Suurmond, J., et al. 2014. Activation of human basophils by combined toll-like receptor- and FcepsilonRI-triggering can promote Th2 skewing of naive T helper cells. European Journal of Immunology 44(2): 386–396.PubMedCrossRef
47.
Zhong, W., et al. 2014. Basophils as a primary inducer of the Th2 immunity in OVA-induced allergic airway inflammation. Immunology.
48.
Liu, J., et al. 2009. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nature Medicine 15(8): 940–945.PubMedCentralPubMedCrossRef
49.
Altintas, M.M., et al. 2011. Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice. Journal of Lipid Research 52(3): 480–488.PubMedCentralPubMedCrossRef
50.
Divoux, A., et al. 2012. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. Journal of Clinical Endocrinology and Metabolism 97(9): E1677–E1685.PubMedCrossRef
51.
Marques-Vidal, P., et al. 2013. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clinical Endocrinology 78(2): 232–241.PubMedCrossRef
52.
Gerner, R.R., et al. 2013. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Canadian Journal of Physiology and Pharmacology 91(11): 867–872.PubMedCrossRef
53.
Pessin, J.E., and H. Kwon. 2012. How does high-fat diet induce adipose tissue fibrosis? Journal of Investigative Medicine 60(8): 1147–1150.PubMedCentralPubMed
54.
55.
Caspar-Bauguil, S., et al. 2005. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Letters 579: 3487–3492.PubMedCrossRef
56.
Bertola, A., et al. 2012. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 61(9): 2238–2247.PubMedCentralPubMedCrossRef
57.
Stefanovic-Racic, M., et al. 2012. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c + cells in adipose tissue and liver. Diabetes 61(9): 2330–2339.PubMedCentralPubMedCrossRef
58.
Hagita, S., et al. 2011. Adipose inflammation initiates recruitment of leukocytes to mouse femoral artery: role of adipo-vascular axis in chronic inflammation. PLoS One 6(5): e19871.PubMedCentralPubMedCrossRef
59.
60.
Auffray, C., et al. 2007. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666–670.PubMedCrossRef
61.
Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71–82.PubMedCrossRef
62.
Shantsila, A., et al. 2013. Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. Hypertension Research 36(6): 546–549.PubMedCrossRef
63.
Nockher, W.A., J. Wiemer, and J.E. Scherberich. 2001. Haemodialysis monocytopenia: differential sequestration kinetics of CD14 + CD16+ and CD14++ blood monocyte subsets. Clinical and Experimental Immunology 123: 49–55.PubMedCentralPubMedCrossRef
64.
Cottam, D.R., et al. 2002. Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. Obesity Surgery 12: 335–342.PubMedCrossRef
65.
Rogacev, K.S., et al. 2010. Monocyte heterogeneity in obesity and subclinical atherosclerosis. European Heart Journal 31: 369–376.PubMedCrossRef
66.
Schlitt, A., et al. 2004. CD14 + CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thrombosis and Haemostasis 92: 419–424.PubMed
67.
Rogacev, K.S., et al. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. European Heart Journal 32: 84–92.PubMedCrossRef
68.
Heine, G.H., et al. 2008. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney International 73: 622–629.PubMedCrossRef
69.
Poitou, C., et al. 2011. CD14dimCD16+ and CD14 + CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 31: 2322–2330.PubMedCrossRef
70.
Matsunawa, M., et al. 2009. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicological Sciences 109: 50–58.PubMedCrossRef
71.
Tsou, C.-L., et al. 2007. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. Journal of Clinical Investigation 117: 902–909.PubMedCentralPubMedCrossRef
72.
Spite, M., et al. 2011. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. Journal of Immunology 187: 1942–1949.CrossRef
73.
Lynch, L., et al. 2012. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 37(3): 574–587.PubMedCrossRef
74.
Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nature Reviews Immunology 5: 953–964.PubMedCrossRef
75.
Martinez, F.O., et al. 2008. Macrophage activation and polarization. Frontiers in Bioscience 13: 453–461.PubMedCrossRef
76.
Lacasa, D., et al. 2007. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 148: 868–877.PubMedCrossRef
77.
Yu, R., et al. 2006. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 14: 1353–1362.CrossRef
78.
Zhuang, G., et al. 2012. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 125(23): 2892–2903.PubMedCrossRef
79.
Duffaut, C., et al. 2009. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochemical and Biophysical Research Communications 384: 482–485.PubMedCrossRef
80.
O’Rourke, R.W., et al. 2009. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. International Journal of Obesity 33(9): 978–990.PubMedCentralPubMedCrossRef
81.
Rocha, V.Z., et al. 2008. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circulation Research 103: 467–476.PubMedCentralPubMedCrossRef
82.
Taniguchi, M., K. Seino, and T. Nakayama. 2003. The NKT cell system: bridging innate and acquired immunity. Nature Immunology 4(12): 1164–1165.PubMedCrossRef
83.
84.
85.
Lynch, L., et al. 2009. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. European Journal of Immunology 39(7): 1893–1901.PubMedCrossRef
86.
Nishimura, S., et al. 2009. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 15: 914–920.PubMedCrossRef
87.
Feuerer, M., et al. 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 15: 930–939.PubMedCentralPubMedCrossRef
88.
Duffaut, C., et al. 2009. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1608–1614.PubMedCrossRef
89.
90.
Khan, I.M., et al. 2014. Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. Atherosclerosis 233(2): 419–428.PubMedCrossRef
91.
Fabbrini, E., et al. 2013. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 145(2): 366.e1-3–374.e1-3.CrossRef
92.
Priceman, S.J., et al. 2013. Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 110(32): 13079–13084.PubMedCentralPubMedCrossRef
93.
Han, J.M., et al. 2014. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. Journal of Immunology 192(2): 623–629.CrossRef
94.
95.
Zhao, R., et al. 2014. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. PLoS One 9(1): e85770.PubMedCentralPubMedCrossRef
96.
Thayer, K.A., et al. 2012. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environmental Health Perspectives 120(6): 779–789.PubMedCentralPubMedCrossRef
97.
Arsenescu, V., et al. 2008. Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Environmental Health Perspectives 116(6): 761–768.PubMedCentralPubMedCrossRef
98.
Arsenescu, V., et al. 2011. Polychlorinated biphenyl 77 augments angiotensin II-induced atherosclerosis and abdominal aortic aneurysms in male apolipoprotein E deficient mice. Toxicology and Applied Pharmacology 257: 148–154.PubMedCentralPubMedCrossRef
99.
Kerley-Hamilton, J.S., et al. 2012. Obesity is mediated by differential aryl hydrocarbon receptor signaling in mice fed a Western diet. Environmental Health Perspectives 120(9): 1252–1259.PubMedCentralPubMedCrossRef
100.
Kerley-Hamilton, J.S., et al. 2012. Inherent and benzo[a]pyrene-induced differential aryl hydrocarbon receptor signaling greatly affects life span, atherosclerosis, cardiac gene expression, and body and heart growth in mice. Toxicological Sciences 126(2): 391–404.PubMedCentralPubMedCrossRef
101.
Esser, C. 2012. Biology and function of the aryl hydrocarbon receptor: report of an international and interdisciplinary conference. Archives of Toxicology 86(8): 1323–1329.PubMedCrossRef
102.
Littman, D.R., and A.Y. Rudensky. 2010. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140: 845–858.PubMedCrossRef
103.
Bailey-Downs, L.C., et al. 2013. Aging exacerbates obesity-induced oxidative stress and inflammation in perivascular adipose tissue in mice: a paracrine mechanism contributing to vascular redox dysregulation and inflammation. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 68(7): 780–792.CrossRef
104.
Police, S.B., et al. 2009. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1458–1464.PubMedCentralPubMedCrossRef
105.
Bigorgne, A.E., et al. 2008. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice. Gastroenterology 134(5): 1459–1469.PubMedCrossRef
106.
Azimi, A., et al. 2013. Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart 99(9): 655–660.PubMedCrossRef
107.
Ito, S., and M. Yoshida. 2014. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins (Basel) 6(2): 665–678.CrossRef
108.
Ito, S., et al. 2010. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. Journal of Biological Chemistry 285: 38869–38875.PubMedCentralPubMedCrossRef
109.
Watanabe, I., et al. 2013. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circulation Journal 77: 224–230.PubMedCrossRef
110.
Gondouin, B., et al. 2013. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International 84(4): 733–744.PubMedCrossRef
111.
Moll, F.L., et al. 2011. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. European Journal of Vascular and Endovascular Surgery 41(Suppl 1): 1–1.CrossRef
112.
Kent, K.C., et al. 2010. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. Journal of Vascular Surgery 52(3): 539–548.PubMedCrossRef
113.
Stackelberg, O., et al. 2013. Obesity and abdominal aortic aneurysm. British Journal of Surgery 100(3): 360–366.PubMedCrossRef
114.
Cronin, O., P.J. Walker, and J. Golledge. 2013. The association of obesity with abdominal aortic aneurysm presence and growth. Atherosclerosis 226(2): 321–327.PubMedCrossRef
115.
Barandier, C., J.P. Montani, and Z. Yang. 2005. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. American Journal of Physiology - Heart and Circulatory Physiology 289(5): H1807–H1813.PubMedCrossRef
116.
Golledge, J., et al. 2007. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation 116(20): 2275–2279.PubMedCrossRef
117.
Eringa, E.C., et al. 2007. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 14(4–5): 389–402.PubMedCrossRef
118.
Schlett, C.L., et al. 2009. Novel measurements of periaortic adipose tissue in comparison to anthropometric measures of obesity, and abdominal adipose tissue. International Journal of Obesity 33(2): 226–232.PubMedCentralPubMedCrossRef
119.
Chatterjee, T.K., et al. 2009. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circulation Research 104(4): 541–549.PubMedCentralPubMedCrossRef
120.
Chatterjee, T.K., et al. 2013. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasis. Physiological Genomics 45(16): 697–709.PubMedCrossRef
121.
Lamers, D., et al. 2011. Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells. Journal of Cellular and Molecular Medicine 15(5): 1177–1188.PubMedCrossRef
122.
Arita, Y., et al. 2002. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105(24): 2893–2898.PubMedCrossRef
123.
Maeda, N., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8(7): 731–737.PubMedCrossRef
124.
Ohashi, K., et al. 2010. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. Journal of Biological Chemistry 285(9): 6153–6160.PubMedCentralPubMedCrossRef
125.
Aghamohammadzadeh, R., et al. 2013. Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. Journal of the American College of Cardiology 62(2): 128–135.PubMedCentralPubMedCrossRef
126.
Ronco, C., et al. 2008. Cardiorenal syndrome. Journal of the American College of Cardiology 52: 1527–1539.PubMedCrossRef
127.
Kelly, K.J., et al. 2008. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. American Journal of Physiology. Renal Physiology 294(5): F1136–F1145.PubMedCrossRef
128.
Ramkumar, N., et al. 2004. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. Journal of Renal Nutrition 14: 201–207.PubMedCrossRef
129.
Nolan, E., Y.M. O’Meara, and C. Godson. 2013. Lipid mediators of inflammation in obesity-related glomerulopathy. Nephrology, Dialysis, Transplantation.
130.
Iseki, K., et al. 2004. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney International 65: 1870–1876.PubMedCrossRef
131.
Sowers, J.R., A. Whaley-Connell, and M.R. Hayden. 2011. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Medicine 1(1): 5–12.PubMedCentralPubMedCrossRef
132.
133.
Ma, L.J., et al. 2011. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. American Journal of Physiology. Renal Physiology 300(5): F1203–F1213.PubMedCentralPubMedCrossRef
134.
Moran, G.W., et al. 2013. The increasing weight of Crohn’s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflammatory Bowel Diseases.
135.
136.
Kondo, H., et al. 2006. Differential regulation of intestinal lipid metabolism-related genes in obesity-resistant A/J vs. obesity-prone C57BL/6J mice. American Journal of Physiology, Endocrinology and Metabolism 291(5): E1092–E1099.CrossRef
137.
Zulian, A., et al. 2012. Visceral adipocytes: old actors in obesity and new protagonists in Crohn’s disease? Gut 61: 86–94.PubMedCrossRef
138.
Arsenescu, V., et al. 2011. Adiponectin and plant-derived mammalian adiponectin homolog exert a protective effect in murine colitis. Digestive Diseases and Sciences 56(10): 2818–2832.PubMedCrossRef
139.
Nishihara, T., et al. 2006. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 131(3): 853–861.PubMedCrossRef
140.
141.
Gandhi, S., et al. 2012. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? American Journal of Medicine 125: 956–962.PubMedCrossRef
142.
Lakatos, P.L., et al. 2011. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease. Inflammatory Bowel Diseases 17(3): 767–777.PubMedCrossRef
143.
Mandal, P., et al. 2011. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. Journal of Biological Chemistry 286: 13460–13469.PubMedCentralPubMedCrossRef
144.
Klinghammer, L., et al. 2013. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis–influence on IP-10, TNF-alpha and MCP-1. Cytokine 62(2): 290–296.PubMedCrossRef
145.
Chujo, D., et al. 2007. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertension Research 30(12): 1205–1210.PubMedCrossRef
146.
Meijers, B.K.I., et al. 2010. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology, Dialysis, Transplantation 25: 219–224.PubMedCrossRef
147.
Niwa, T. 2011. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis 15: 120–124.PubMedCrossRef
148.
Konishi, K., et al. 2008. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Research and Clinical Practice 81: 310–315.PubMedCrossRef
149.
Nakamura, T., et al. 2004. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney and Blood Pressure Research 27: 121–126.PubMedCrossRef
150.
Schroeder, J.C., et al. 2010. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 49: 393–400.PubMedCentralPubMedCrossRef
151.
152.
Rosenblum, J.L., et al. 2012. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. American Journal of Clinical Nutrition 95: 101–108.PubMedCentralPubMedCrossRef
153.
Poonawalla, A.H., et al. 2013. Adipose tissue MRI for quantitative measurement of central obesity. Journal of Magnetic Resonance Imaging 37: 707–716.PubMedCentralPubMedCrossRef
Metadata
Title
Adipose Tissue Immune Response: Novel Triggers and Consequences for Chronic Inflammatory Conditions
Authors
Giorgio Ghigliotti
Chiara Barisione
Silvano Garibaldi
Patrizia Fabbi
Claudio Brunelli
Paolo Spallarossa
Paola Altieri
Gianmarco Rosa
Giovanni Spinella
Domenico Palombo
Razvan Arsenescu
Violeta Arsenescu
Publication date
01-08-2014
Publisher
Springer US
Published in
Inflammation / Issue 4/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9914-1

Other articles of this Issue 4/2014

Inflammation 4/2014 Go to the issue

OriginalPaper

Elevated Serum IL-21 Levels in Hantavirus-Infected Patients Correlate with the Severity of the Disease

OriginalPaper

Modular Analysis of Bioinformatics Demonstrates a Critical Role for NF-κB in Macrophage Activation

OriginalPaper

SUMO-Conjugating Enzyme UBC9 Promotes Proliferation and Migration of Fibroblast-like Synoviocytes in Rheumatoid Arthritis

OriginalPaper

Overexpression of Fas and FasL Is Associated with Infectious Complications and Severity of Experimental Severe Acute Pancreatitis by Promoting Apoptosis of Lymphocytes

Letter

Anti-Inflammatory Action of Isorhamnetin

OriginalPaper

Kaempferol Inhibits IL-1β-Stimulated, RANKL-mediated Osteoclastogenesis via Downregulation of MAPKs, c-Fos, and NFATc1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits